IPF Clinical Trial
Official title:
Turkish Validity and Reliability of the Saint George Respiratory Questionnaire Idiopathic Pulmonary Fibrosis Version (SGRQ-I)
NCT number | NCT05147597 |
Other study ID # | TR_SGRQI |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | January 9, 2022 |
Est. completion date | January 1, 2025 |
The Saint George Respiratory Questionnaire (SGRQ) questionnaire is a frequently used questionnaire in the respiratory patient group, and the Turkish version of this questionnaire, which was created for use in idiopathic pulmonary fibrosis patients, is not available. There is no commonly used quality of life questionnaire in patients with idiopathic pulmonary fibrosis. The aim of the study is to translate and validate the SGRQ idiopathic pulmonary fibrosis version of questionnaire into Turkish.
Status | Recruiting |
Enrollment | 180 |
Est. completion date | January 1, 2025 |
Est. primary completion date | January 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Be over 18 years old - Having a Diagnosis of Idiopathic Pulmonary Fibrosis - To be literate in Turkish Exclusion Criteria: - Exacerbation or exacerbation in the last 6 weeks - Presence of comorbidities affecting ambulation - Cognitive impairment |
Country | Name | City | State |
---|---|---|---|
Turkey | Esra Pehlivan | Istanbul | Üsküdar |
Lead Sponsor | Collaborator |
---|---|
Saglik Bilimleri Universitesi |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Saint George Respiratory Questionnaire - Idiopathic Pulmonary Fibrosis Version (SGRQ-I) | SGRQ-I consists of 34 self-complementing items. It was developed as an IPF-specific version of SGRQ. Different scales are used to score the SGRQ-I, resulting in an overall score and three domain scores: Effects, Activities, and Symptoms. Scores range from 0 to 100, with higher scores indicating more impaired health related quality of life. | Change from baseline at 1 week. | |
Secondary | Saint George's Respiratory Questionnaire (SGRQ) | It is a 76-item questionnaire in which the total score and the three-component score are calculated. Components; symptoms (difficulty caused by symptoms such as cough, sputum, shortness of breath, and wheezing), activity (activity that causes or is limited by shortness of breath), and impact (social and psychological impact of the illness). Each item has its own weighted score. These weighted scores are not dependent on age, gender, disease duration and severity. It is not focused on a single language and culture. The evaluation feature of the questionnaire and its distinctiveness in different diseases and at different levels are high. Each of these scores ranges from 0 to 100. 0 indicates best health, 100 indicates worst health. | Change from baseline at 1 week. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05570058 -
Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Recruiting |
NCT02807025 -
Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases
|
N/A | |
Recruiting |
NCT05895565 -
A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects
|
Phase 1 | |
Completed |
NCT03211507 -
Idiopathic Pulmonary Fibrosis Job Exposures Study
|
||
Completed |
NCT02503657 -
Safety and Tolerability Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
Recruiting |
NCT03873298 -
Inhaled NO in IPF and COPD During 6 Minute Walk Test
|
Phase 2 | |
Terminated |
NCT03864328 -
A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF
|
Phase 2 | |
Completed |
NCT05803850 -
A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058
|
Phase 1 | |
Withdrawn |
NCT05349760 -
A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Completed |
NCT01266317 -
Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
|
Phase 1/Phase 2 | |
Completed |
NCT04503044 -
ILAs in CT Lung Cancer Screening Population
|
||
Recruiting |
NCT04564183 -
Advancing Prevention of Pulmonary Fibrosis
|
||
Recruiting |
NCT05190211 -
Telerehabilitation in Patients With Idiopathic Pulmonary Fibrosis
|
N/A | |
Recruiting |
NCT04263727 -
A Study of Patients With Chronic Disease
|
||
Completed |
NCT05353556 -
Effects of Home-based Inspiratory Muscle Training in Patients With IPF
|
N/A | |
Completed |
NCT02976935 -
Functional MR Lung Imaging Using Hyperpolarised 129Xe
|
||
Recruiting |
NCT05193136 -
Sleep Hygiene, Sarcopenia, and Cognitive Function in Respiratory Disease
|
||
Recruiting |
NCT06181370 -
Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF
|
Phase 1 | |
Not yet recruiting |
NCT02885961 -
The Coagulation Cascade in Idiopathic Pulmonary Fibrosis
|
N/A | |
Completed |
NCT02151435 -
Prospective Evaluation of Biomarker Profiles in Idiopathic Pulmonary Fibrosis
|
N/A |